Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2269-2273

  Skov, Vibe ^a   Riley, Caroline Hasselbalch ^b   Thomassen, Mads ^a   Larsen, Thomas Stauffer ^a   Jensen, Morten K ^b   Bjerrum, Ole Weis ^b   Kruse, Torben A ^a   Hasselbalch, Hans Carl ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Defective tumor immune surveillance; Essential thrombocythemia; HLA genes; Myelofibrosis; Polycythemia; Vera; Whole blood transcriptional profiling

Indexed keywords

ALPHA2 INTERFERON; BETA 2 MICROGLOBULIN; DNA; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERFERON; METHIONYL AMINOPEPTIDASE 2; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HLA SYSTEM; HUMAN; IMMUNOSURVEILLANCE; MALE; MYELOFIBROSIS; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; THROMBOCYTHEMIA; TRANSCRIPTION REGULATION;

ALLELES; CASE-CONTROL STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84884492836     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.764417     Document Type: Article

References (47)

1. Campbell P J, G reen A R. Mechanisms of disease: The myelo1-proliferative disorders. N Engl J Med 2006; 355: 2452-2466.
2. Skov V, Larsen TS, Thomassen M, et al. Whole blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 2011; 87: 54-60.
3. Skov V, Larsen T S, Thomassen M, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 2012; 40: 771-780.
4. Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for infl ammation and immune surveillance. Leuk Res 2012; 36: 1387-1392.
5. Hasselbalch HC. Perspectives on chronic infl ammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic infl ammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119: 3219-3225.
6. Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4 + CD25+ Foxp3 + c ells in patients with Philadelphia-negative chronic myeloproliefrative neoplasms during treatment with intererferon-alpha. Blood 2011; 118: 2170-2173.
7. d e Castro F A, P alma P V, M orais F R, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 2003; 44: 2061-2067.
8. Gabriele L, Borghi P, Rozera C, et al. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 2004; 103: 980-987.
9. Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 2012; 96: 1-9.
10. Glauche I, Horn K, Horn M, et al. Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: Simulation studies of different treatment combinations. Br J Cancer 2012; 106: 1742-1752.
11. Brodsky FM, Guagliardi LE. The cell biology of antigen processing and presentation. Annu Rev Immunol 1991; 9: 707-744.
12. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA classiphenotypes in human tumours. Immunol Today 1997; 18: 89-95.
13. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-158.
14. Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA classiantigens in human tumors. Semin Cancer Biol 2012; 22: 350-358.
15. Seliger B. Novel insights into the molecular mechanisms of HLA classiabnormalities. Cancer Immunol Immunother 2012; 61: 249-254.
16. Demanet C, Mulder A, Deneys V, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells:an escape mechanism from CTL and NK attack? Blood 2004; 103: 3122-3130.
17. Majumder D, Bandyopadhyay D, Chandra S, et al. Analysis of HLA class Ia transcripts in human leukaemias. Immunogenetics 2005; 57: 579-589.
18. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24: 756-764.
19. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comp Graph Stat 1996; 5: 299-314.
20. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
21. Smyth G K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
23. Berkofsky-Fessler W, Buzzai M, Kim M K, et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 2010; 16: 4339-4352.
24. Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA classigenes in human esophageal squamous cell carcinomas. Carcinogenesis 2001; 22: 1615-1623.
25. Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA classiantigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer 2001; 94: 243-251.
26. Ye Q, Shen Y, Wang X, et al. Hypermethylation of HLA classigene is associated with HLA classidown-regulation in human gastric cancer. Tissue Antigens 2009; 75: 30-39.
27. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosomenegative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009; 18: 2068-2073.
28. Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study. Blood 2011; 118: 6515-6520.
29. Suzuki H, Toyota M, Kondo Y, et al. Infl ammation-related aberrant patterns of DNA methylation: Detection and role in epigenetic deregulation of cancer cell transcriptome. Methods Mol Biol 2009; 512: 55-69.
30. Stenvinkel P, Karimi M, Johansson S, et al. Impact of infl ammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease? J Intern Med 2007; 261: 488-499.
31. Kato S, Lindholm B, Stenvinkel P, et al. DNA hypermethylation and infl ammatory markers in incident Japanese dialysis patients. Nephron Extra 2012; 2: 159-168.
32. Garrido C, Paco L, Romero I, et al. MHC classimolecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 2012; 33: 687-693.
33. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: A report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116: 3735-3742.
34. Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740-747.
35. Rambaldi A, Dellacasa C M, F inazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446-455.
36. Vannucchi A M, B iamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011; 96: 1398-1402.
37. Lykkegaard Andersen C, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythemia vera and essential thrombocythemia. Blood 2012; 120: Abstract 803.
38. Hasselbalch HC. A new era for IFN-a in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011; 4: 637-655.
39. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117: 4706-4715.
40. Yanai Y, Sanou O, Yamamoto K, et al. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes. Cancer Lett 2002; 185: 173-179.
41. Brouwer RE, van der HP, Schreuder GM, et al. Loss or downregulation of HLA classiexpression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002; 63: 200-210.
42. Burchert A, Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 2005; 46: 167-175.
43. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-893.
44. Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 2010; 70: 906-915.
45. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFNalpha: Implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010; 43: 204-209.
46. Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha interferon2b in polycythemia vera: A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009; 14: 331-334.
47. Hasselbalch HC. Chronic infl ammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human infl ammation model for cancer development? Leuk Res 2012 Nov 20. [Epub ahead of print]